Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $123
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Merck & Co (NYSE:MRK) but has lowered the price target from $130 to $123.
November 01, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Merck & Co but reduced the price target from $130 to $123, indicating a more cautious outlook.
The reduction in price target by Morgan Stanley suggests a more cautious outlook on Merck's stock performance, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100